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AbstrAct
Objective Mild cognitive impairment (MCI) is prevalent 
in atrial fibrillation (AF) and has the potential to contribute 
to poor outcomes. We investigated the influence of MCI 
on survival and rehospitalisation in patients with chronic 
forms of AF undergoing a home-based, AF-specific disease 
management intervention (home-based intervention (HBI)) 
or standard management (SM).
Methods The Montreal Cognitive Assessment tool was 
administered at baseline (a score of <26/30 indicated MCI) 
in patients with AF randomised to HBI versus SM. Post 
hoc analyses of mortality and rehospitalisations during 
a minimum 24-month follow-up were conducted in the 
overall cohort and in each study group separately.
Results Of 260 patients (mean age 72±11, 47% female), 
65% demonstrated MCI on screening (34% in SM; 31% 
in HBI). Overall, the number of days spent alive and out-
of-hospital during follow-up (P=0.012) and all-cause 
rehospitalisation were influenced by MCI during follow-up 
(OR 3.16 (95% CI 1.46 to 6.84)) but MCI did not influence any 
outcomes in the SM group. However, survival was negatively 
influenced by MCI in the HBI group (P=0.036); those with 
MCI in this group were 5.6 times more likely to die during 
follow-up (OR 5.57 (95% CI 1.10 to 28.1)). Those with MCI in 
the HBI group also spent less days alive and out-of-hospital 
than those with no MCI (P=0.022). MCI was also identified 
as a significant independent correlate of shortest duration 
of event-free survival (OR 3.48 (95% CI 1.06 to 11.4)), all-
cause rehospitalisation (OR 3.30 (95% CI 1.25 to 8.69)) and 
cardiovascular disease (CVD)-related rehospitalisation (OR 
2.35 (95% CI 1.12 to 4.91)) in this group.
Conclusions The effectiveness of home-based, disease 
management for patients with chronic forms of AF is 
negatively affected by comorbid MCI. The benefit of 
adjunctive support for patients with MCI on CVD-related 
health outcomes requires further investigation.
IntROduCtIOn
Atrial fibrillation (AF) is the most common 
cardiac rhythm disturbance observed in clin-
ical practice. AF is prevalent in 2%–3% of 
the general population, and more than 70% 
of individuals with AF are aged 65 years and 
older.1 Prevalence of AF is rising in parallel to 
population ageing, improved survival from 
other clinical conditions that increase the like-
lihood of AF development and little progress in 
reducing major significant risk factors such as 
obesity.1 Multiple complications are the direct 
result of AF, including thromboembolic events 
(notably stroke), heart failure, reduced quali-
ty-of-life and death.2 3 
Key questions
What is already known about this subject?
 ► Mild cognitive impairment (MCI) is a common 
comorbidity in atrial fibrillation (AF) and influences 
a patient’s ability to self-care and perform simple 
daily tasks. Cognitive impairment is becoming 
increasingly recognised as exerting a powerful and 
negative impact on the risk profile, management 
and prognosis of patients with AF.
What does this study add?
 ► Patient outcomes of a cohort of patients with 
AF were affected by MCI. The presence of 
MCI in patients with AF undergoing standard 
postdischarge management did not influence 
survival or rehospitalisation. However, the benefit of 
a postdischarge, AF-specific disease management 
intervention was negatively influenced by the 
presence of MCI. The risk of death for AF patients 
with comorbid MCI in the intervention group 
was increased 5.6-fold, and MCI was the only 
independent predictor of rehospitalisation during 
minimum 24-month follow-up, increasing the 
risk by over threefold. Patients without MCI in 
the intervention group had significantly less 
unplanned, all-cause and cardiovascular-specific 
hospitalisations during follow-up compared with 
those with MCI.
How might this impact on clinical practice?
 ► Successful patient care can be influenced by the 
presence of MCI. Therefore, all older patients with 
AF should be screened for MCI to allow care to be 
individualised and tailored accordingly. Adjunctive 
support for those with MCI may go somewhat 
towards optimising the health outcomes of these 
patients.
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AF is associated with the most common forms of throm-
boembolism (stroke risk is increased fivefold in patients 
with AF) and responsible for subtle brain changes due to 
the occurrence of silent cerebral infarcts, microemboli, 
microbleeds and cerebral hypoperfusion.4–8 The result is 
gradual cognitive dysfunction beginning with mild cogni-
tive impairment (MCI), which markedly influences the 
ability of patients to self-care and perform simple daily 
tasks such as taking prescribed medications.9 AF is inde-
pendently associated with cognitive decline, and patients 
with AF are at twofold higher risk of cognitive impair-
ment than age-matched patients without AF.10 11 Cogni-
tive impairment is becoming increasingly recognised 
as exerting a powerful and negative impact on the risk 
profile, management and prognosis of patients with AF.12 
Higher rates of morbidity, symptom severity, healthcare 
utilisation and mortality resulting from the negative 
impact of cognitive impairment have been observed 
in older individuals (some with heart failure and other 
cardiovascular conditions)13–16 and the same is likely to 
be observed in AF populations. AF patients with cogni-
tive impairment have poorer anticoagulation adherence, 
more frequent cardiovascular events and demonstrate 
greater functional impairment compared with those 
without cognitive impairment.12 Additionally, patients 
with MCI are vulnerable to mood disorders including 
depression17 with psychosocial and cognitive comor-
bidities clustering frequently in patients with AF.14 The 
resulting psychosocial and cognitive multimorbidity 
exerts a powerful and negative effect on AF-specific 
quality of life.14
With the continued evolution of individualised care 
to optimise AF management,18 it is imperative to under-
stand the influence of cognitive impairment on the effec-
tiveness of care for patients with AF. Therefore, we aimed 
to investigate the influence of MCI on the outcomes 
(namely mortality, days alive and out-of-hospital and 
rehospitalisations) of patients hospitalised as a result of 
AF. Furthermore, we aimed to examine the impact of MCI 
on the outcomes of patients participating in an AF-spe-
cific disease management programme compared with 
those undergoing standard postdischarge management.
MetHOds
study setting
Details of the Standard versus Atrial Fibrillation spEcific 
managemenT strategY  (SAFETY) Trial protocol19 and 
primary composite endpoint outcomes of death or 
unplanned rehospitalisation due to any cause20 have 
been reported previously. Briefly, 335 inpatients (52% 
male) from three tertiary referral hospitals in Australia 
with a diagnosis of chronic forms of AF (recurrent parox-
ysmal, persistent or permanent AF) were randomly 
assigned into the study. Participants were randomised 
(via a computer-generated protocol and using block 
groups) to either standard management (SM; n=167) 
or an AF-specific home-based management intervention 
(HBI; n=168) aimed at reducing morbidity and mortality 
following hospital discharge. Nurse-led clinic visits were 
conducted at 12 and 24 months for follow-up assessment 
of surviving patients, with comprehensive details of all 
deaths and rehospitalisations collected.
The SAFETY Trial was prospectively registered with 
the Australian New Zealand Clinical Trials Registry 
(ANZCTRN: 12610000221055) and was Consolidated 
Standards of Reporting Trials compliant with outcomes 
reported appropriately for a pragmatic trial comparing 
the efficacy of two non-pharmacological health inter-
ventions.21 Written informed consent was obtained from 
each study participant prior to any study procedure being 
conducted. The study protocol conformed to the ethical 
guidelines of the Declaration of Helsinki.
Participants
Using a systematic screening programme to identify 
eligible participants, inpatients were approached for 
recruitment if they were aged 45 years or older, had a 
documented diagnosis of a chronic form of AF (persistent 
or permanent AF), would be living independently in the 
community or their own home postdischarge and were 
able and willing to provide written informed consent to 
participate. Those who had a primary diagnosis of valvular 
heart disease, had a transient form of AF, were scheduled 
for catheter ablation and/or had concurrent heart failure 
(confirmed on echocardiography (including screening 
for evidence of diastolic heart failure) and defined as 
displaying New York Heart Association class III–IV symp-
toms with a documented left ventricular ejection fraction 
of less than 45%) were excluded from participation. Also 
excluded from participation were those who had a docu-
mented diagnosis of cognitive impairment, delirium or 
dementia and those who were not proficient in under-
standing or conversing in English (ie, those unable to 
provide informed consent).
Baseline cohort profiling
Comprehensive baseline profiling was conducted in all 
participants during index hospitalisation. Data were 
collected on sociodemographic status, past medical 
history (including AF-specific details), inhospital and 
planned postdischarge management, prescribed ther-
apeutics, thromboembolic risk (calculated by the 
CHA2DS2-VASc score
22), comorbid conditions including 
calculation of an age-adjusted Charlson Comorbidity 
Index score23 and cognitive status (determined by the 
Montreal Cognitive Assessment (MoCA) tool24). The 
MoCA is a 10 min, 30-item screening tool for MCI. A 
cut-off score of 26 (range 0–30) has been shown to have 
high sensitivity (0.90) and specificity (0.87) for detecting 
MCI.24 To account for differences in education attained, 
one point is added to the total score for those with ≤12 
years of formal education (education level-corrected 
scores of below 26 are considered as being cognitively 
‘impaired’).24 The MoCA was administered to n=260 of 
the total cohort of 335 patients. Patients who did not 
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undertake the MoCA were those who were physically 
unable to do so (eg, due to vision disturbance) and those 
from non-English speaking backgrounds who may have 
been proficient in English but for whom the MoCA has 
not been validated.
study intervention
The study intervention involved proactive patient 
management to optimise gold standard pharmacolog-
ical and non-pharmacological management according 
to guidelines. Structured postdischarge care consisted of 
an initial home visit conducted by an intervention nurse 
at 7–14 days postdischarge and a combination of tele-
phone follow-up and repeat home visits. The initial home 
visit, which involved a comprehensive assessment of each 
patient, was performed including evaluation of medica-
tion adherence, self-care, disease knowledge and clinical 
status (blood pressure, international normalised ratio 
where appropriate, current symptoms and heart rate and 
rhythm (12-lead ECG)). A postvisit needs assessment of 
each participant was conducted including risk stratifica-
tion based on visit findings and determination of level 
of intervention required to maintain (or achieve) clinical 
stability during follow-up. Clinic reviews were conducted 
at 12 and 24 months postdischarge. Components of the 
individualised management were specifically focused on 
AF and included advanced clinical assessment (including 
the use of Holter monitoring), a review of social circum-
stances, education, review of medications and treat-
ment plan according to gold standards, identification of 
barriers to self-care and communication with or referral 
to other healthcare providers and community services.
statistical analyses
Descriptive data are presented as mean (with SD) or 
median (with IQR) for continuous variables or as a 
proportion (%) for categorical variables. Between-group 
comparisons were conducted with Student’s t-test, χ2 test 
or Mann-Whitney U test where appropriate.
We performed Kaplan-Meier survival analyses in the 
overall cohort and in the SM and HBI groups separately 
to assess survival from all-cause mortality and time to the 
primary endpoint of mortality and unplanned readmis-
sion (measured as days alive and out-of-hospital) in partic-
ipants classified as having MCI (MoCA scores <26/30) 
versus those of normal cognition (MoCA scores ≥26/30). 
Group comparisons were performed with a log-rank test. 
Mean survival time (with 95% CIs) was calculated for 
each respective group. As the number of potential covari-
ates was large relative to the sample size, only covariates 
that were empirically related to outcomes were included. 
Covariates were identified using multiple logistic regres-
sion with backwards, stepwise selection for: all-cause 
mortality, inclusion in the lower quartile of days alive and 
out-of-hospital (≤763 days), all-cause hospital admission 
and hospital admission due to cardiovascular disease 
(CVD). All multiple logistic regression models included 
sociodemographic (age and gender), lifestyle (current 
smoking), medical history/status (MCI, hypertension, 
cerebrovascular disease and type 2 diabetes) and treat-
ment factors (rate/rhythm control, beta blocker, calcium 
channel blocker, ACE inhibitor, angiotensin II receptor 
blocker, digoxin and warfarin prescription), and all 
models were stratified by group of randomisation (SM vs 
HBI). MCI was initially entered into all statistical models 
as a binary variable (‘Yes’ vs ‘No’). To test the interaction 
of randomisation group with MCI status, we replaced MCI 
in the overall regression models with a four-group vari-
able (noMCI-HBI, MCI-HBI, noMCI-SM and MCI-SM). 
All data were analysed using SPSS V.22.0. A probability 
value of P<0.05 (two sided) was considered statistically 
significant.
Results
Baseline profile
Baseline characteristics of SAFETY participants stratified 
by randomisation group and MCI are presented in table 1. 
Of the total cohort, 65% demonstrated MCI on screening 
(n=89 (34%) in SM and n=80 (31%) in HBI). Overall, 
this cohort included older patients (mean age 72±11 
years) at high thromboembolic and clinical risk (mean 
CHA2DS2-VASc score 3.6±1.8) and suffering from multi-
morbidity (mean Charlson Comorbidity Index 5.0±2.5). 
Within the SM group, those with MCI were significantly 
older (mean age 74 years vs 68 years, respectively), at 
higher thromboembolic risk (mean CHA2DS2-VASc 
score 4.0 vs 2.8, respectively) and suffering from signif-
icantly more comorbidity (mean Charlson Comorbidity 
Index score 5.6 vs 4.3, respectively) than those without 
MCI. The same patterns were identified within the HBI 
group. Although, in addition, significantly less partici-
pants with MCI obtained tertiary-level education (24% vs 
44%, respectively) and significantly more suffered from 
vascular disease and were prescribed digoxin therapy 
compared with those without MCI (10% vs 0% and 44% vs 
23%, respectively).
survival
All-cause mortality
Figure 1 shows the unadjusted survival curves of partic-
ipants with and without MCI in the overall cohort 
(figure 1A) and in the SM (figure 1B) and HBI (figure 1C) 
groups separately. Over a mean follow-up of 879±299 days, 
40 individuals died overall (15.4%) including 31/169 
participants (18.3%) with MCI and 9/91 (9.9%) without 
MCI. Mean survival time in these groups was 1209 days 
(95% CI 1149 to 1269 days) and 1255 days (95% CI 1187 
to 1324) days, respectively. Within the SM group, over 
a mean follow-up of 874±289 days, 24 individuals died 
(18.2%) including 17/89 participants (19.1%) with MCI 
and 7/43 (16.3%) without MCI. Mean survival time in 
these groups was 1206 days (95% CI 1129 to 1284 days) 
and 1187 days (95% CI 1068 to 1306 days), respectively. 
Within the HBI group, over a mean follow-up of 884±310 
days, 16 individuals died (12.5%) including 14/80 
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participants (17.5%) with MCI and 2/48 (4.2%) without 
MCI. Mean survival time in these groups was 1206 days 
(95% CI 1116 to 1297) days and 1315 (95% CI 1248 to 
1382) days, respectively. Figure 1A,B demonstrates no 
significant difference in mortality between those with 
or without MCI in the cohort overall (log rank P=0.089) 
and in the SM group (log rank P=0.740). However, in the 
HBI group (figure 1C), a significant difference in survival 
was demonstrated with MCI sufferers experiencing worse 
survival than those without MCI (log-rank P=0.036). 
Multiple logistic regression performed on the cohort 
overall revealed that increasing age (OR 1.17 (95% CI 
1.10 to 1.24), P<0.001) and current smoking (OR 4.97 
(95% CI 1.63 to 15.13), P=0.005) were predictive of 
all-cause mortality during study follow-up (table 2). The 
same predictors were identified on analysis in the SM 
group. In addition to increasing age, participants in the 
HBI group were over 5.5 times more likely to die if they 
had MCI (OR 5.57 (95% CI 1.10 to 28.1), P=0.038). No 
interaction between randomisation group and MCI status 
was identified for all-cause mortality (data not shown).
Event-free survival (days alive and out-of-hospital)
Figure 2 shows the unadjusted Kaplan-Meier curves for 
the primary endpoint (time to mortality and unplanned 
readmission) of participants with and without MCI in 
the overall cohort (figure 2A) and in the SM (figure 2B) 
and HBI (figure 2C) groups separately. During follow-up, 
206 individuals died or had an unplanned readmission 
overall (79.2%) including 145/169 participants (85.8%) 
with MCI and 61/91 (67.0%) without MCI. Mean 
number of days alive and out-of-hospital in these groups 
was 411 days (95% CI 344 to 477) and 554 days (95% CI 
446 to 663) days, respectively. Within the SM group, 
110 individuals died or had an unplanned readmission 
(83.3%) including 77/89 participants (86.5%) with MCI 
and 33/43 (76.7%) without MCI. Mean number of days 
alive and out-of-hospital in these groups was 422 days 
(95% CI 334 to 510) and 498 days (95% CI 372 to 624), 
respectively. Within the HBI group, 96 individuals died 
or had an unplanned readmission (75.0%) including 
68/80 participants (85.0%) with MCI and 28/48 (58.3%) 
without MCI. Mean number of days alive and out-of-hos-
pital in these groups was 392 days (95% CI 294 to 490) 
and 602 days (95% CI 435 to 769), respectively. No signif-
icant difference in time to the primary endpoint was 
demonstrated in the SM group between those with or 
without MCI (figure 2B; log rank P=0.263). However, in 
the cohort overall and in the HBI group (figure 2A,C), 
a significant difference in the number of days alive and 
out-of-hospital was demonstrated with MCI sufferers 
experiencing death or unplanned readmission earlier 
than those without MCI (log-rank P=0.012 and P=0.022, 
respectively).
On adjusted analyses (table 2) in the overall cohort, 
age (OR 1.09 (95% CI 1.05 to 1.13), P<0.001), current 
smoking (OR 2.54 (95% CI 1.04 to 6.19), P=0.040) and 
comorbid type 2 diabetes (OR 2.04 (95% CI 1.04 to 4.00), 
Figure 1 Unadjusted survival from all-cause mortality 
of participants with and without MCI in (A) overall cohort, 
(B) standard management cohort and (C) home-based 
intervention cohort. MCI, mild cognitive impairment.
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P=0.039) were significantly predictive of experiencing 
the shortest duration of event-free survival (ie, inclusion 
in the lower quartile of days alive and out-of-hospital). 
Only age and current smoking were significantly predic-
tive of the same in the SM group (OR 1.09 (95% CI 1.04 
to 1.14), P<0.001 and OR 5.07 (95% CI 1.62 to 15.91), 
P=0.005, respectively). MCI was significantly associated 
with patients having fewer days alive and out-of-hos-
pital in the HBI group (OR 3.48 (95% CI 1.06 to 11.4), 
P=0.039) in addition to increasing age and comorbid 
type 2 diabetes (table 2).  Online supplementary table 1 
demonstrates the results of analyses conducted to under-
stand the interaction between randomisation group and 
MCI status. Compared with individuals in the HBI group 
with no MCI, the odds of experiencing the shortest dura-
tion of event-free survival for those with MCI in the HBI 
group were more than tripled and for those with MCI in 
the SM group, the odds were almost quadrupled.
Hospital readmissions and stay
All-cause rehospitalisation
Table 3 demonstrates the results of multiple logistic 
regression analyses identifying independent correlates 
of all-cause rehospitalisation. In the overall cohort, MCI 
increased the risk of rehospitalisation due to any cause 
by over three times during follow-up (OR 3.16 (95% CI 
1.46 to 6.84), P=0.003). Smoking and type 2 diabetes 
significantly decreased the risk of all-cause rehospitali-
sation (OR 0.39 (95% CI 0.15 to 0.99), P=0.048 and OR 
0.36 (95% CI 0.15 to 0.83), P=0.017, respectively). In the 
SM group, risk of all-cause rehospitalisation was signifi-
cantly increased with increasing age (OR 1.07 (95% CI 
1.02 to 1.34), P=0.012) and, again, significantly reduced 
in smokers and those with type 2 diabetes. The only 
independent correlate of all-cause rehospitalisation in 
the HBI group was MCI, which more than tripled the 
risk of all-cause rehospitalisation (OR 3.30 (95% CI 1.25 
to 8.69), P=0.016). Online supplementary table 1 also 
demonstrates that compared with individuals in the HBI 
group with no MCI, the odds of experiencing all-cause 
rehospitalisation for those with MCI in the HBI group 
were almost quadrupled, and for those with MCI in the 
SM group, the odds were increased fivefold.
CVD-related rehospitalisation
Digoxin significantly increased the risk of CVD-related 
rehospitalisation in the cohort overall and in the SM 
group. In a similar pattern to all-cause rehospitalisation, 
the only independent correlate of CVD-related rehospi-
talisation in the HBI group was MCI (table 3). Those with 
MCI were over twofold more likely to be hospitalised due 
to CVD during follow-up (OR 2.35 (95% CI 1.12 to 4.91), 
P=0.024). No interaction between randomisation group 
and MCI status was identified for CVD-related rehospital-
isation (data not shown).
dIsCussIOn
In a typically older and clinically complex AF patient 
population, we found that the health outcomes of patients 
undergoing a nurse-led, AF-specific disease management 
intervention were negatively impacted by the presence of 
MCI. Overall, MCI influenced the number of days spent 
alive and out-of-hospital and all-cause rehospitalisation 
Table 2  Independent correlates of survival (all-cause mortality and event-free survival via lower quartile of days alive and 
out-of-hospital) overall and in HBI and SM groups separately
All-cause mortality
OR (95% CI)
Lower quartile of days alive and out-of-hospital
OR (95% CI)
All SM HBI All SM HBI
Sociodemographic profile
  Age (years) 1.17 
(1.10 to 1.24)**
1.20 
(1.10 to 1.31)**
1.08 
(1.00 to 1.16)*
1.09 
(1.05 to 1.13)**
1.09 
(1.04 to 1.14)**
1.08 
(1.02 to 1.13)*
Risk factor profile
  Mild cognitive impairment – – 5.57 
(1.10 to 28.1)*
2.04 
(0.98 to 4.25)
– 3.48 
(1.06 to 11.4)*
  Current smoker† 4.97 
(1.63 to 15.13)*
9.63 
(2.25 to 41.21)*
2.54 
(1.04 to 6.19)*
5.07 
(1.62 to 15.91)*
– 
Comorbidity profile
  Type 2 diabetes 2.23 
(0.96 to 5.19)
– – 2.04 
(1.04 to 4.00)*
– 2.97 
(1.34 to 7.77)*
Treatment profile
  Digoxin – – 0.08 
(0.01 to 0.69)*
– – – 
*P<0.05.
**P<0.001.
†Assessed in n=258 patients.
 HBI, home-based intervention; SM, standard management.
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of the cohort during follow-up (but not mortality or 
CVD-related hospitalisation) and did not influence any 
outcomes for those in the SM group. However, signifi-
cantly worse outcomes were experienced by those in the 
HBI group who had MCI. Survival was significantly influ-
enced by MCI; these individuals were at over 5.5 times 
the risk of dying. This diminished survival was driven, at 
least in part, by reduced event-free survival; those with 
MCI in the HBI group were 3.5 times more likely to expe-
rience the shortest duration of event-free survival during 
follow-up. Furthermore, MCI was the only independent 
correlate of all-cause and CVD-related rehospitalisation 
in the HBI group. When the interaction between rando-
misation group and MCI status was analysed, significant 
differences in event-free survival and all-cause rehospi-
talisation were demonstrated between those with and 
without MCI but not between HBI and SM.
To our knowledge, this is the first study to demonstrate a 
significant disadvantage to health outcomes (survival and 
rehospitalisations) associated with the implementation of 
a disease management intervention in those with AF and 
MCI. This phenomenon has, however, been identified 
previously in the context of heart failure. Findings of a 
study comparing a heart failure-specific disease manage-
ment intervention with SM demonstrated that MCI was 
of prognostic importance even when a disease-specific 
intervention was applied.25 Similarly, a study investi-
gating the impact of a self-care training intervention to 
reduce hospital readmissions in heart failure patients 
with MCI found that despite increasing patient knowl-
edge, readmission rates were not reduced.26 Conversely, 
in a study conducted by Ketterer and colleagues, a heart 
failure-specific disease management intervention imple-
mented in patients with comorbid MCI resulted in a 30% 
reduction in early readmission compared with a control 
group.27 In this study, those with MCI were provided 
additional support including conducting a discussion 
with the patient by all members of their treatment team 
about the effect of cognitive impairment on adher-
ence to their complex medication regimens, provision 
of cognitive impairment-specific psychoeducation and 
the involvement of family members to act as healthcare 
collaborators.27
HBI appears highly effective for patients without 
MCI but has relatively little benefit in those with MCI. 
Given that a potent effect of MCI was identified in the 
HBI group only, it is possible that a disease-specific 
intervention of this design is too confusing for those 
who already have difficulty with information processing 
and executive functioning. It may not be appropriate to 
apply such a comprehensive (and potentially complex) 
intervention in this patient group. It is also possible that 
application of information provided in this format is 
confronting and may trigger health-related anxiety for 
those with MCI. The result may be a lack of confidence 
in self-management, reduced self-care and declining clin-
ical stability. The reasons behind the lack of effectiveness 
in this patient group is likely to be multifactorial, but 
Figure 2 Unadjusted event-free survival (days alive and out-
of-hospital) of participants with and without MCI in (A) overall 
cohort, (B) standard management cohort and (C) home-
based intervention cohort. MCI, mild cognitive impairment.
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an intervention that is not tailored towards addressing 
cognitive dysfunction potentially should not be imple-
mented. For the intervention to be effective in patients 
with AF and comorbid MCI, integration with healthcare 
systems (such as psychology and nursing organisations) 
and a programme design that explicitly caters for cogni-
tively impaired patients is critical. This may also involve 
care givers more prominently.
Despite the potential for the findings of this work to be 
considered as part of a ‘generic’ phenomenon (given it 
is also seen in heart failure), the high prevalence of MCI 
in patients with AF means that these individuals should 
still be considered at high risk for an ‘adverse’ reaction to 
AF (particularly in older individuals) and management 
must be tailored in response. Therefore, the findings 
of this study carry substantial clinical significance and 
support the need for engaging in patient-centred care 
and individualised, integrated management for those 
with AF. Evidence-based care of AF patients that maxi-
mises effectiveness, safety and efficiency is the ultimate 
goal and, therefore, enhanced recognition of cognitive 
impairment and more proactive patient management is 
necessary. In addition, screening for MCI should become 
routine practice for patients with AF with results used to 
inform the relevance, application and content of AF-spe-
cific disease management.
limitations
There exist some study limitations that require comment. 
First, we employed only one method for MCI detec-
tion, although the MoCA is a quick and easy tool that 
demonstrates enhanced sensitivity to early impairment, 
unlike other screening tools.28 Additionally, the entire 
SAFETY Trial cohort was not screened for MCI due to 
issues with vision and not originating from an English-
speaking background; selection bias may have been 
introduced as a result causing underestimation or over-
estimation of MCI in this cohort and findings that are 
not representative. The number of events was also rela-
tively small in the cohort potentially affecting the accu-
racy and/or generalisability of results. Generalisability 
may also be affected due to this study being conducted 
within the Australian urban context with the inclusion 
of participants principally of European descent. Further-
more, this was a selected population of patients with AF 
who did not have heart failure, a common comorbidity. 
Age, thromboembolic risk (CHA2DS2-VASc score) and 
severity of comorbidity (Charlson Comorbidity Index) 
was significantly different at baseline between those with 
and without MCI in both study groups, although these 
factors were adjusted for in all statistical models. Finally, 
we acknowledge that differences detected in this study 
Table 3  Independent correlates of rehospitalisation (all cause and CVD related) overall and in HBI and SM groups separately
All-cause rehospitalisation
OR (95% CI)
CVD-related rehospitalisation
OR (95% CI)
All SM HBI All SM HBI
Sociodemographic profile
  Age (years) – 1.07 
(1.02 to 1.34)*
– – – – 
  Sex (female/male) – – – – 2.10 
(0.95 to 4.61)
– 
Risk factor profile
  Mild cognitive impairment 3.16 
(1.46 to 6.84)*
– 3.30 
(1.25 to 8.69)*
1.60 
(0.94 to 2.74)
– 2.35 
(1.12 to 4.91)*
  Current smoker† 0.39 
(0.15 to 0.99)*
0.15 
(0.03 to 0.66)*
– – – – 
Comorbidity profile
  Type 2 diabetes 0.36 
(0.15 to 0.83)*
0.18 
(0.04 to 0.79)*
– – – – 
Treatment profile
  Calcium channel blocker – – – – 2.57 
(0.87 to 7.63)
– 
  Angiotensin II receptor 
blocker
2.50 
(0.89 to 7.04)
8.82 
(0.84 to 92.54)
– – – – 
  Digoxin – – – 1.84 
(1.05 to 3.24)*
2.58 
(1.08 to 6.16)*
– 
*P<0.05.
**P<0.001. 
†Assessed in n=258 patients.
CVD, cardiovascular disease; HBI, home based intervention; SM, standard management.
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may have arisen due to multiple testing and type I error. 
However, this was a hypothesis-driven statistical analysis 
(rather than exploratory) and is consistent with previous 
findings in heart failure cohorts. Using a more conserva-
tive statistical approach (eg, applying Bonferonni correc-
tion) would have reduced study power, which needs to 
be conserved given the number of events observed and 
stratification of the cohort into those with and without 
MCI. Therefore, the statistical analyses conducted were 
appropriate and consistent with the data.
COnClusIOns
We found that the benefit of a home-based, AF-specific 
disease management intervention for patients with AF was 
affected by patient cognitive function. MCI was associated 
with increased mortality and healthcare usage of patients 
with chronic forms of AF. Therefore, routine screening 
and detection is critical to direct patient care and optimise 
management. Future research is required to: (1) further 
investigate the influence of MCI particularly on the self-
care and self-management of patients with AF; (2) further 
elucidate the relationship between MCI and different forms 
of AF patient management; and (3) assess the effectiveness 
of an AF-specific disease management intervention that 
includes adjunctive support for patients with MCI.
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